• Local precision, by design

  ANGel starts with peritumoral / perilesional subcutaneous (SC) administration—not systemic-first delivery.

  • Designed to focus exposure in the tissue region that matters
  • Formulation strategy aimed at reducing unnecessary systemic exposure burden
  • Built with co delivery / co activation in mind from the beginning

• Combination by design

  Combination isn’t an add-on feature—it’s the architecture.

  • Enables multi antibody combinations to pursue bispecific inspired multi mechanism at the formulation level
  • Structured to test and expand mechanism driven strategies (including immune escape hypotheses) quickly
  • Designed to scale across combinations without rebuilding the platform each time

• ADC like action, built through formulation

  ANGel approaches ADC like behavior through a payload strategy—small molecule loading + tuned release profile—rather than relying on complex antibody engineering or conjugation-heavy formats.

  • Less dependence on complicated molecular re engineering
  • Formulation design governs when, where, and how much payload activity is expressed

• Sustained exposure profile

  ANGel is designed around persistence at the delivery site—engineering exposure duration as a formulation outcome, not a hope.

  • Sustained local exposure informed by tissue residence considerations
  • Development direction aimed at lower dosing frequency and patient friendly regimens (to be clinically demonstrated)

Why it matters

Clinical relevance without overpromising
ANGel is not positioned as a guaranteed outcome—it’s a platform designed to increase the probability that combination biology can translate by engineering exposure conditions.

• Targeted exposure: design where exposure happens (peritumoral/perilesional focus)
• Personalized combinations: configure combinations by indication and mechanism
• Sustained profile: design for persistence at the delivery site
• Reformulation advantage: build on validated assets to reduce development risk
• Scalable platform: modular architecture to expand across combinations and indications

Platform advantage

Spec driven. Tech transfer ready.
ANGel is built to be diligence-ready: it’s defined by specifications and reproducibility—not just concept.

• CQA-defined specifications (examples): particle size/PDI, dispersion stability, antibody binding level, drug loading, release profile
• Batch to batch reproducibility
• Standardized manufacturing + QC SOPs (CMC documentation) designed for partner review and transfer planning

Business model

Not “selling a product”—designing repeatable platform deployment.
The model is B2B partnering-first, built for programs where approved or clinically validated assets can be upgraded via formulation.

• Platform out licensing (L/O) and co development with global pharma/biotech
• Multi layer economics: upfront + milestones + royalties (plus funded research where applicable)

Investment thesis

Conviction comes from the execution path: Data → Deal → Clinic
We prioritize proof packages that convert into partner decisions, then clinical entry.

• Proof (data): GLP toxicology + PoC + CMC standardization → a diligence-ready dataset
• Deal (conversion): meeting → PoC design → option / co development / licensing
• Clinic (credibility): clinical entry is the platform’s credibility inflection point